###begin article-title 0
Promoter methylation of RASSF1A and DAPK and mutations of K-ras, p53, and EGFR in lung tumors from smokers and never-smokers
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 361 404 361 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras-association domain isoform A (RASSF1A) </italic>
###xml 412 451 412 451 <italic xmlns:xlink="http://www.w3.org/1999/xlink">death-associated protein kinase (DAPK) </italic>
###xml 670 673 670 673 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras</italic>
###xml 675 678 675 678 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53</italic>
###xml 684 689 684 689 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 477 485 <span type="species:ncbi:9606">patients</span>
###xml 628 636 <span type="species:ncbi:9606">patients</span>
Epidemiological studies indicate that some characteristics of lung cancer among never-smokers significantly differ from those of smokers. Aberrant promoter methylation and mutations in some oncogenes and tumor suppressor genes are frequent in lung tumors from smokers but rare in those from never-smokers. In this study, we analyzed promoter methylation in the ras-association domain isoform A (RASSF1A) and the death-associated protein kinase (DAPK) genes in lung tumors from patients with primarily non-small cell lung cancer (NSCLC) from the Western Pennsylvania region. We compare the results with the smoking status of the patients and the mutation status of the K-ras, p53, and EGFR genes determined previously on these same lung tumors.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 28 36 28 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A </italic>
###xml 40 45 40 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAPK </italic>
###xml 143 146 143 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras</italic>
###xml 148 151 148 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53</italic>
###xml 157 162 157 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
Promoter methylation of the RASSF1A and DAPK genes was analyzed by using a modified two-stage methylation-specific PCR. Data on mutations of K-ras, p53, and EGFR were obtained from our previous studies.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 4 12 4 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A </italic>
###xml 310 315 310 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAPK </italic>
###xml 628 636 628 636 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A </italic>
###xml 639 644 639 644 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAPK </italic>
###xml 708 717 708 717 <italic xmlns:xlink="http://www.w3.org/1999/xlink">-ras, p53</italic>
###xml 723 728 723 728 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 85 93 <span type="species:ncbi:9606">patients</span>
###xml 422 430 <span type="species:ncbi:9606">patients</span>
The RASSF1A gene promoter methylation was found in tumors from 46.7% (57/122) of the patients and was not significantly different between smokers and never-smokers, but was associated significantly in multiple variable analysis with tumor histology (p = 0.031) and marginally with tumor stage (p = 0.063). The DAPK gene promoter methylation frequency in these tumors was 32.8% (40/122) and did not differ according to the patients' smoking status, tumor histology, or tumor stage. Multivariate analysis adjusted for age, gender, smoking status, tumor histology and stage showed that the frequency of promoter methylation of the RASSF1A or DAPK genes did not correlate with the frequency of mutations of the K-ras, p53, and EGFR gene.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 24 32 24 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A </italic>
###xml 36 41 36 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAPK </italic>
###xml 262 265 262 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras</italic>
###xml 267 271 267 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 275 280 275 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 213 221 <span type="species:ncbi:9606">patients</span>
Our results showed that RASSF1A and DAPK genes' promoter methylation occurred frequently in lung tumors, although the prevalence of this alteration in these genes was not associated with the smoking status of the patients or the occurrence of mutations in the K-ras, p53 and EGFR genes, suggesting each of these events may represent independent event in non-small lung tumorigenesis.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 143 144 143 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 584 589 584 589 <italic xmlns:xlink="http://www.w3.org/1999/xlink">-ras </italic>
###xml 599 603 599 603 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 664 668 664 668 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR</italic>
###xml 772 776 772 776 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras </italic>
###xml 839 840 839 840 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 841 842 841 842 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 849 854 849 854 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 917 918 917 918 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 919 920 919 920 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 949 953 949 953 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 1123 1124 1123 1124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 1125 1126 1125 1126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 119 126 <span type="species:ncbi:4097">tobacco</span>
###xml 369 377 <span type="species:ncbi:9606">patients</span>
###xml 1113 1121 <span type="species:ncbi:9606">patients</span>
Lung cancer, the leading cause of cancer-related death in the Unites States and worldwide, is strongly associated with tobacco smoke exposure [1]. In spite of extensive studies, the etiology of lung cancer remains poorly understood. Particularly, studies of lung cancer among never-smokers are few and little is known about the etiology of lung cancer in never-smoking patients. Some studies showed that the frequencies and/or patterns of genetic and epigenetic alterations in some genes in lung tumors from smokers differ from those in never-smokers. For instance, mutations in the K-ras oncogene, p53 tumor suppressor gene, and epidermal growth factor receptor (EGFR) gene have been found frequently in lung tumors and implicated in lung tumorigenesis. However, while K-ras mutations were detected primarily in lung tumors from smokers [2-4], the EGFR mutations were found mostly in lung tumors from never-smokers [5-7]. Furthermore, although the p53 mutations were detected in lung tumors from both smokers and never-smokers, the mutation types and spectra were different between the two groups of lung cancer patients [3,8].
###end p 11
###begin p 12
###xml 232 233 232 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 234 236 234 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 336 379 336 379 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras-association domain isoform A (RASSF1A) </italic>
###xml 387 426 387 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink">death-associated protein kinase (DAPK) </italic>
###xml 560 567 560 567 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1 </italic>
###xml 724 726 724 726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 772 780 772 780 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A </italic>
###xml 784 791 784 791 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1C</italic>
###xml 818 820 818 820 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 821 823 821 823 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 854 862 854 862 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A </italic>
###xml 1007 1009 1007 1009 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 1010 1012 1010 1012 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1019 1024 1019 1024 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAPK </italic>
###xml 1320 1322 1309 1311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 1325 1330 1314 1319 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAPK </italic>
###xml 1397 1399 1386 1388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1416 1421 1405 1410 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAPK </italic>
###xml 1542 1547 1531 1536 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAPK </italic>
###xml 1591 1593 1580 1582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1594 1596 1583 1585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 452 459 <span type="species:ncbi:4097">tobacco</span>
###xml 890 895 <span type="species:ncbi:9606">human</span>
###xml 1448 1453 <span type="species:ncbi:9606">human</span>
In addition to mutations in oncogenes and tumor suppressor genes, results from previous studies demonstrated that promoter methylation of some genes occurred more frequently in lung tumors from smokers, compared with never-smokers [9-13]. Other genes whose transcription has been found frequently inactivated in lung tumors include the ras-association domain isoform A (RASSF1A) and the death-associated protein kinase (DAPK) genes, but the effects of tobacco smoking on the prevalence of promoter methylation of these genes in lung tumors remain unclear. The RASSF1 gene is located at 3p21.3 and functions as a tumor suppressor gene involved in cell apoptosis, genomic and microtubule stability, and cell cycle regulation [14]. This gene codes for two major transcripts, RASSF1A and RASSF1C, by alternative splicing [15,16]. Promoter methylation of the RASSF1A gene has been found in many human tumors, including those of the lung where it was detected in 30% to 50% of non-small cell lung cancer (NSCLC) [16,17]. The DAPK gene is located on chromosome 9p34.1. It encodes for a Ca+/calmodulin-regulated serine/threonine kinase involved in apoptosis induced by interferon-gamma, tumor necrosis factor alpha, activated Fas, transforming growth factor beta, ceramide and detachment of cells from the extracellular matrix [18]. DAPK suppresses tumor growth by increasing the occurrence of apoptosis [19]. Expression of DAPK is frequently lost in many human cancers, often as a result of silencing by DNA methylation. Promoter methylation of the DAPK gene has been found in 20% to 40% of NSCLC [20,21].
###end p 12
###begin p 13
###xml 190 192 190 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 237 242 237 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink">-ras </italic>
###xml 292 294 292 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 295 297 295 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 448 455 448 455 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1 </italic>
###xml 553 555 553 555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 566 574 566 574 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A </italic>
###xml 616 624 616 624 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1C </italic>
###xml 625 627 625 627 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 628 630 628 630 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 633 641 633 641 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A </italic>
###xml 676 683 676 683 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1C</italic>
###xml 787 789 787 789 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 790 792 790 792 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 800 808 800 808 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A </italic>
###xml 888 890 888 890 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 893 901 893 901 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A </italic>
###xml 1004 1006 1004 1006 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 1020 1028 1020 1028 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A </italic>
It has been suggested that epigenetic changes might addict cells to certain oncogenic pathways, predisposing cells to the accumulations of genetic mutations, which drives tumor progression [22]. On the other hand, overexpression of the K-ras gene can affect the activity of methytransferase [23,24] and potentially the methylation activity and regulation of gene transcription. Several studies have indicated the presence of an association between RASSF1 and Ras proteins. For instance, Ras binds RASSF1C in a GTP-dependent manner to mediate apoptosis [25]. Because RASSF1A has the identical Ras associate domain as RASSF1C [15,16], RASSF1A may bind Ras in the same manner as RASSF1C. Furthermore, Ras may also promote apoptosis through its association with a Nore-RASSF1-Mst 1 complex [26,27] since RASSF1A was found to be the closest Ras effector homologue to Nore1 in mammalian cells [15]. RASSF1A forms heterodimers with Nore1 through its non-homologous NH2-terminal segments and interacts with Ras [28]. Therefore, RASSF1A may serve as a Ras effector to mediate apoptosis.
###end p 13
###begin p 14
###xml 176 180 176 180 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ARF </sup>
###xml 181 183 181 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 404 406 404 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 407 409 407 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
DAPK and p53 may interact to mediate apoptosis. Raveh et al demonstrated that DAPK executes its anti-oncogenic action through activation of p53 in a mechanism that requires p19ARF [29] and failure to perform apoptosis may result in tumorigenesis. Other studies showed that DAPK may also exert its p53-mediated suppressive effects on oncogenic transformation by imposing growth arrest, apoptosis or both [30,31].
###end p 14
###begin p 15
###xml 9 14 9 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 176 181 176 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 228 233 228 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 401 403 401 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 500 505 500 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 571 573 571 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 574 576 574 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 693 697 693 697 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR</italic>
###xml 704 709 704 709 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 773 774 773 774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 775 776 775 776 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 1183 1191 1183 1191 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A </italic>
###xml 1195 1200 1195 1200 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAPK </italic>
###xml 1340 1344 1340 1344 <italic xmlns:xlink="http://www.w3.org/1999/xlink">-ras</italic>
###xml 1346 1350 1346 1350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 1354 1359 1354 1359 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 1225 1233 <span type="species:ncbi:9606">patients</span>
###xml 1403 1411 <span type="species:ncbi:9606">patients</span>
Although EGFR mutations have been found frequently in lung tumors, the relationship between these mutations and promoter methylation in these tumors has not been well studied. EGFR is a 170 kDa trans-membrane glycoprotein. When EGFR binds to specific ligands, multiple signaling pathways are activated, including the RAS/RAF/ERK/MAPK pathway, resulting in cell proliferation, and the p13/AKT pathway [32]. Recently, it has been demonstrated that mutations in the tyrosine kinase domain region of the EGFR gene in NSCLC predict the response to tyrosine kinase inhibitors [33,34] and enable the identification of the subpopulation of lung cancers that are likely to respond to drugs targeted to EGFRs. The EGFR mutations were found consistently more common in never-smokers [5-7], indicating different pathways for lung tumorigenesis between smokers and never-smokers. Although both genetic and epigenetic alterations in oncogenes and tumor suppressor genes have been identified frequently in lung tumors, the interaction among these gene alterations and their significance in lung cancer remains poorly understood. In this study, we analyzed methylation in the promoter region of the RASSF1A and DAPK genes in 122 lung cancer patients. We compared the results with those reported by previous studies and with the status of mutations in the K-ras, p53 and EGFR genes in the same lung tumors obtained from patients from the Western Pennsylvania region.
###end p 15
###begin title 16
Methods
###end title 16
###begin p 17
###xml 459 460 459 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 77 85 <span type="species:ncbi:9606">patients</span>
###xml 431 439 <span type="species:ncbi:9606">patients</span>
###xml 473 481 <span type="species:ncbi:9606">patients</span>
###xml 529 536 <span type="species:ncbi:9606">patient</span>
###xml 560 567 <span type="species:ncbi:9606">patient</span>
###xml 667 675 <span type="species:ncbi:9606">patients</span>
###xml 725 733 <span type="species:ncbi:9606">patients</span>
Lung tumor tissues analyzed in this study were obtained from 122 lung cancer patients, including 81 smokers and 41 never-smokers, all of whom were Caucasian and lived in the Western Pennsylvania region. All 122 tumors were among specimens collected between 1988 and 2001 and stored at the University of Pittsburgh Medical Center under an Institutional Review Board-approved protocol. The demographic and clinical profiles of these patients are shown in table 1. Of the 122 patients, 120 had NSCLC while 2 had SCLC, including one patient with carcinoid and one patient with neuroendocrine carcinoma. Most of the never-smokers were females (31/41, or 75.6%) while male patients accounted for 24.4% (10/41). The male and female patients among the smokers were 51.9% (42/81) and 48.1% (39/81), respectively.
###end p 17
###begin p 18
Each lung tumor was histologically examined by a pathologist to identify the type and other clinical characteristics of the tumor. Any contamination of tumor cells by non-tumor cells was described by the pathologist. Most of the cells in these lung tumor samples were tumor cells. DNA was extracted from fresh-frozen tissues, using the Proteinase K treatment and phenol/chloroform method, and was dissolved in distilled water and stored at -20degreesC until use.
###end p 18
###begin title 19
Methylation-specific PCR (MSP)
###end title 19
###begin p 20
###xml 195 197 195 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 221 226 <span type="species:ncbi:9606">human</span>
Each genomic DNA sample was treated with sodium bisulfite (Sigma, Saint Louis, MO) and purified by using a Wizard DNA Clean-Up System (Promega Corporation, Madison, WI), as described previously [12]. Universal methylated human DNA (Chemicon International, Temecula, CA) was treated the same way and was used as a positive control DNA, and water was used as blank controls.
###end p 20
###begin p 21
###xml 86 88 86 88 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 254 256 254 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 1070 1078 1070 1078 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A </italic>
###xml 1082 1087 1082 1087 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAPK </italic>
###xml 1133 1135 1133 1135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 1285 1286 1284 1285 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1449 1458 1428 1437 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A) </italic>
###xml 1477 1481 1450 1454 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAPK</italic>
###xml 1759 1761 1719 1721 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 2170 2177 2112 2119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A</italic>
###xml 2198 2202 2134 2138 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAPK</italic>
###xml 2331 2338 2249 2256 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A</italic>
###xml 2359 2363 2271 2275 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAPK</italic>
Two versions of MSP have been previously reported, including an original 1-stage MSP [35], and a modified 2-stage MSP that used 2 rounds of PCR and had a higher level of sensitivity to detect promoter methylation, compared with the original 1-stage MSP [36]. We first compared the sensitivity and validity of both MSP methods to analyze promoter methylation of these genes in DNA from some lung tumors. The results showed that promoter methylation was detected in the same tumors and at a similar frequency by using either the original or modified MSP for these genes, suggesting that the original 1-stage MSP was sufficiently sensitive to detect promoter methylation in lung tumors. However, in our experiments, the 2-stage MSP method showed MSP-products as one clear single band by gel electrophoresis analysis, while the 1-stage MSP method provided products that usually appeared with other minor bands (data not shown). Therefore, in this study, we applied a sensitive modified 2-stage MSP. The nucleotide sequences of the primers used for MSP analysis for both the RASSF1A and DAPK were the same as described by Belinsky et al [37]. During the stage-I PCR, the PCR amplification was carried out in a 25-mul reaction mixture containing 10 mM Tris-HCL (pH 8.3), 50 mM KCL, 2 mM MgCl2, 100 muM each dNTP, and 0.2 muM each primer. The reaction was heated at 95degreesC for 10 min., then amplified for 40 cycles [95degreesC/30 sec., 64degreesC (for RASSF1A) or 58degreesC (for DAPK)/30 sec., and 72degreesC/30 sec.], followed by a 10-min.-final extension at 72degreesC. Three microliters of each stage-I PCR product was diluted 10-fold with water and 1-mul was used for stage-II PCR, using the same reagents and conditions as for stage-I, except that the MgCl2 concentration was reduced to 1 mM and each sample was amplified in duplicated reaction, with one reaction containing primers specific for a methylated C and the other reaction containing primers specific for unmethylated C. Each reaction was heated at 95degreesC for 10 min., then amplified for 40 cycles each consisting, for the reaction containing methylated primers, of 95degreesC/30 sec., 68degreesC (for RASSF1A) or 66degreesC (for DAPK)/30 sec., and 72degreesC/30 sec., and, for the reaction containing unmethylated primers, of 95degreesC/30 sec., 64degreesC (for RASSF1A) or 68degreesC (for DAPK)/30 sec., and 72degreesC/30 sec., followed by a 10-min.-final extension at 72degreesC. Five microliters of each stage-II PCR product was separated on an 8% polyacrylamide gel. The gel was stained with ethidium bromide and photographed under UV illumination. The reproducibility of the results was confirmed by repeating the MSP analysis for each DNA sample. A portion of PCR products were purified using a MinElute PCR purification kit (QIAGEN, Valencia, CA) and directly sequenced to confirm methylation.
###end p 21
###begin title 22
###xml 15 18 15 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras</italic>
###xml 20 23 20 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53</italic>
###xml 29 34 29 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
Detection of K-ras, p53, and EGFR mutations
###end title 22
###begin p 23
###xml 22 27 22 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">-ras </italic>
###xml 47 51 47 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 70 75 70 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 136 137 136 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 138 140 138 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 141 143 141 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
Data on mutations in K-ras (codons 12 and 13), p53 (exons 5 - 8), and EGFR (exons 18-21) genes were obtained from our previous studies [2,38,39].
###end p 23
###begin title 24
Statistical analysis
###end title 24
###begin p 25
Chi-square test or Fisher's exact test was used in univariate analysis. Logistic regression models were used to assess the effect of multiple variables on methylation status and relationship between genetic and epigenetic alterations.
###end p 25
###begin title 26
Results
###end title 26
###begin p 27
###xml 9 17 9 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A </italic>
###xml 423 428 423 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAPK </italic>
###xml 724 729 724 729 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAPK </italic>
###xml 76 84 <span type="species:ncbi:9606">patients</span>
###xml 463 471 <span type="species:ncbi:9606">patients</span>
###xml 503 510 <span type="species:ncbi:9606">patient</span>
Overall, RASSF1A promoter methylation was detected in 46.7% (57/122) of the patients, a frequency that did not differ between smokers and never-smokers [48.1% (39/81) vs. 43.9% (18/41), p = 0.645], or between adenocarcinoma and the group of other tumor types [51.4% (37/72) vs. 40% (20/50), p = 0.210], or between stage-I and the group of other stages [51.9% (28/54) vs. 40.7% (22/54), p = 0.247]. Promoter methylation for DAPK was found in 32.8% (40/122) of the patients. When grouped according to the patient's smoking status, this gene methylation was detected in 34.6% (28/81) of the smokers and was not significantly different from the 29.3% (12/41) frequency observed among the never-smokers (p = 0.567). Furthermore, DAPK promoter methylation frequency did not differ between adenocarcinoma and the group of other tumor types [34.7% (25/72) vs. 30% (15/50), p = 0.583], or between stage-I and the group of other stages [31.5% (17/54) vs. 31.5% (17/54), p = 1.000].
###end p 27
###begin p 28
###xml 211 219 211 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A </italic>
###xml 223 228 223 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAPK </italic>
###xml 253 254 253 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 350 358 350 358 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A </italic>
###xml 361 366 361 366 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAPK </italic>
###xml 396 404 396 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A </italic>
###xml 772 777 772 777 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAPK </italic>
Multivariate logistic regression models were employed to control for the potential confounding effects of variables, such as age, gender, smoking status, tumor histology and tumor stage on methylation status of RASSF1A and DAPK genes. As shown in Table 2, age, gender, and smoking status did not significantly affect the methylation frequency of the RASSF1A or DAPK gene. Promoter methylation of RASSF1A was associated significantly with adenocarcinoma [the group of other tumor types vs. adenocarcinoma: odds ratio (OR) = 0.661, 95% confidence interval (CI) = 0.454-0.962, p = 0.031], and marginally with early tumor stage (the group of other stages vs. stage-I: OR = 0.673, 95% CI = 0.444 - 1.022, p = 0.063). Neither tumor histology nor tumor stage was associated with DAPK promoter methylation.
###end p 28
###begin p 29
###xml 39 43 39 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 86 90 86 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 91 93 91 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 113 121 113 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A </italic>
###xml 159 163 159 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 264 268 264 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 310 315 310 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAPK </italic>
###xml 363 367 363 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 447 451 447 451 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 14 22 <span type="species:ncbi:9606">patients</span>
###xml 145 153 <span type="species:ncbi:9606">patients</span>
###xml 240 248 <span type="species:ncbi:9606">patients</span>
###xml 349 357 <span type="species:ncbi:9606">patients</span>
###xml 423 431 <span type="species:ncbi:9606">patients</span>
Among the 122 patients, 32 (26.2%) had p53 mutations whereas 90 (73.8%) had wild-type p53 [38]. The frequency of RASSF1A promoter methylation in patients with p53 mutations was 56.3% (18/32) and was not significantly different from that in patients with wild-type p53 [43.3% (39/90), p = 0.212]. Likewise, the DAPK promoter methylation frequency in patients with p53 mutations was 25% (8/32) and not different from that in patients with wild-type p53 [35.6% (32/90), p = 0.331].
###end p 29
###begin p 30
###xml 43 49 43 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-ras </italic>
###xml 89 94 89 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">-ras </italic>
###xml 95 96 95 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 110 115 110 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">-ras </italic>
###xml 160 168 160 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A </italic>
###xml 303 308 303 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink">-ras </italic>
###xml 348 353 348 353 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAPK </italic>
###xml 407 412 407 412 <italic xmlns:xlink="http://www.w3.org/1999/xlink">-ras </italic>
###xml 470 475 470 475 <italic xmlns:xlink="http://www.w3.org/1999/xlink">-ras </italic>
###xml 30 38 <span type="species:ncbi:9606">patients</span>
###xml 133 141 <span type="species:ncbi:9606">patients</span>
###xml 278 286 <span type="species:ncbi:9606">patients</span>
###xml 430 438 <span type="species:ncbi:9606">patients</span>
###xml 443 451 <span type="species:ncbi:9606">patients</span>
Thirty-six (29.5%) of the 122 patients had K-ras mutations and 86 (70.5%) had wild-type K-ras [2]. Among the K-ras mutation-positive patients, the frequency of RASSF1A promoter methylation was 41.7% (15/36) and was closely similar to the 48.8% (42/86) frequency in the group of patients with wild-type K-ras (p = 0.474). Likewise, the frequency of DAPK promoter methylation was closely similar between the K-ras mutation-positive patients and patients with a wild-type K-ras [30.6% (11/36) vs. 33.7% (29/86), p = 0.735].
###end p 30
###begin p 31
###xml 9 14 9 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 61 63 61 63 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 183 188 183 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 408 412 408 412 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras </italic>
###xml 500 501 500 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 502 503 502 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 504 506 504 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 507 509 507 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 528 533 528 533 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 574 578 574 578 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 690 695 690 695 <italic xmlns:xlink="http://www.w3.org/1999/xlink">-ras </italic>
###xml 706 710 706 710 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 746 751 746 751 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 810 811 810 811 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 814 819 814 819 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 876 884 876 884 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A </italic>
###xml 887 892 887 892 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAPK </italic>
###xml 107 115 <span type="species:ncbi:9606">patients</span>
###xml 236 244 <span type="species:ncbi:9606">patients</span>
Data for EGFR mutations were obtained from a previous study [39] and were available for only 70 of the 122 patients involved in this study, including 40 never-smokers and 30 smokers. EGFR mutations were detected in 14.3% (10/70) of the patients and exclusively among the never-smokers (10/40, or 25%), including 9 females and one male, and none among the smokers (p = 0.002), and inversely correlated with K-ras mutations [0% (0/10) vs. 28.3% (17/60), p = 0.049], in agreement with previous reports [6,7,13,40]. For comparison, EGFR mutations were found in both tumors with p53 mutations and those without these mutations [30% (3/10) vs. 28.3% (17/60), p = 0.912], suggesting that, unlike K-ras mutations, p53 mutations can occur in concert with EGFR mutations, in agreement with Kosaka's report (p = 0.4634) [6]. EGFR mutations did not correlate with promoter methylation of RASSF1A or DAPK (data not shown).
###end p 31
###begin p 32
###xml 119 127 119 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A </italic>
###xml 130 134 130 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAPK</italic>
###xml 158 162 158 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras </italic>
###xml 165 169 165 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 195 200 195 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink">-ras </italic>
###xml 790 795 790 795 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 11 19 <span type="species:ncbi:9606">patients</span>
###xml 251 259 <span type="species:ncbi:9606">patients</span>
###xml 350 358 <span type="species:ncbi:9606">patients</span>
###xml 416 424 <span type="species:ncbi:9606">patients</span>
###xml 893 901 <span type="species:ncbi:9606">patients</span>
Of the 122 patients, 100 (81.9%) showed alterations of at least one gene, consisting of either promoter methylation of RASSF1A or DAPK, or mutations in the K-ras or p53 gene. Furthermore, since K-ras mutations were found mostly among smokers, smoking patients showed a higher fraction of tumors with gene alterations, compared with the never-smoking patients [87.6% (71/81) vs. 70.7% (29/41), p = 0.022]. Of the 100 patients with alterations of at least one gene, 46 (46%), 43 (43%), and 11 (11%) showed alterations affecting one gene, two genes, and three or more genes, respectively. The frequency of cases with more than one gene abnormality did not differ between adenocarcinoma and the group of other tumor types, or between stage I and the group of other stages (data not shown). The EGFR mutations were not included in the calculation because they were available for only 70 of the 122 patients.
###end p 32
###begin title 33
Discussion
###end title 33
###begin p 34
###xml 25 33 25 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A </italic>
###xml 142 144 142 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 213 214 213 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 258 260 258 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 261 263 261 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 264 266 264 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 319 320 319 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 394 396 394 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 397 399 397 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
The overall frequency of RASSF1A promoter methylation of 46.7% (57/122) in our study is similar to that found by Marsit et al [47% (83/178)] [17] and correlated significantly with adenocarcinoma (p = 0.031, table 2), in agreement with some previous studies [11,17,41], and marginally with tumor stage (p = 0.063, table 2). On the other hand, studies by Kim et al showed no such an association [42,43].
###end p 34
###begin p 35
###xml 25 30 25 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAPK </italic>
###xml 152 154 152 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 218 219 218 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 253 255 253 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 296 297 296 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 373 378 373 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAPK </italic>
###xml 454 456 454 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 530 532 530 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 725 733 725 733 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A </italic>
###xml 737 742 737 742 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAPK </italic>
###xml 834 842 834 842 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A </italic>
###xml 860 864 860 864 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAPK</italic>
###xml 872 873 872 873 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 925 927 925 927 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 928 930 928 930 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 931 933 931 933 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 934 936 934 936 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 586 594 <span type="species:ncbi:9606">patients</span>
###xml 678 686 <span type="species:ncbi:9606">patients</span>
###xml 794 802 <span type="species:ncbi:9606">patients</span>
The overall frequency of DAPK promoter methylation of 32.8% (40/122) found in the present study is in line with that reported by Toyooka's 37% (14/38) [44] and was not associated with tumor histology (p = 0.111, table 2), in agreement with Kim's study [21], or with tumor stage (p = 0.348, table 2). Data from previous studies are conflicting. For instance, in Kim's study DAPK promoter methylation was associated with advanced stages NSCLC (p = 0.009) [21], whereas in Russo's study it was detected mostly in early stages NSCLC [45]. This discrepancy might be due to limited number of patients in Russo's study (n = 49) and/or tumor stage data that were not available for some patients in our study. The frequencies of both RASSF1A and DAPK gene promoter methylation were independent from the patients' smoking status (p = 0.990 for RASSF1A and p = 0.275 for DAPK, table 2), consistent with the results of previous studies [10,11,41,46].
###end p 35
###begin p 36
###xml 257 261 257 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras </italic>
###xml 264 268 264 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 274 276 274 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 277 279 277 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 280 282 280 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 483 485 483 485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 486 488 486 488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 544 552 544 552 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A </italic>
###xml 556 561 556 561 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAPK </italic>
###xml 580 583 580 583 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras</italic>
###xml 585 589 585 589 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 593 598 593 598 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 462 470 <span type="species:ncbi:9606">patients</span>
###xml 639 647 <span type="species:ncbi:9606">patients</span>
There have been a few studies investigating the relationship between aberrant promoter methylation and mutations in oncogenes and tumor suppressor genes. Most of these studies compared promoter methylation of one or two genes with mutations in either the K-ras or p53 gene [41,43,46]. Only two recent studies investigated the relationship between mutations of multiple oncogenes and/or tumor suppressor genes and promoter methylation patterns but in lung cancer patients from Japan [13,40]. Here, we compared the promoter methylation status of RASSF1A and DAPK and mutations of K-ras, p53 and EGFR in the same lung tumors from lung cancer patients from the Western Pennsylvania region.
###end p 36
###begin p 37
###xml 30 38 30 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A </italic>
###xml 88 93 88 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">-ras </italic>
###xml 152 154 152 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 155 157 155 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 158 160 158 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 161 163 161 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 226 231 226 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">-ras </italic>
###xml 392 399 392 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A</italic>
###xml 422 430 422 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A </italic>
###xml 489 497 489 497 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A </italic>
###xml 558 562 558 562 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ras </italic>
###xml 606 614 606 614 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A </italic>
###xml 813 815 813 815 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 849 854 849 854 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAPK </italic>
###xml 907 912 907 912 <italic xmlns:xlink="http://www.w3.org/1999/xlink">-ras </italic>
###xml 966 968 966 968 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 969 971 969 971 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 990 995 990 995 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAPK </italic>
###xml 1021 1026 1021 1026 <italic xmlns:xlink="http://www.w3.org/1999/xlink">-ras </italic>
We observed no association of RASSF1A gene promoter methylation frequency with that of K-ras mutations (p = 0.474), in agreement with previous studies [11,41,43,46], or with the types of amino acid changes at codon 12 of the K-ras gene (data not shown). Activated Ras has been associated with enhanced proliferation, transformation, and cell survival through a series of effectors, including RASSF1A. However, because the RASSF1A gene is a tumor suppressor gene, it is likely that loss of RASSF1A expression by promoter methylation in NSCLC does not require Ras activation. Thus, our findings suggest that RASSF1A inactivation may induce malignant transformation by some distinct mechanisms other than Ras-mediated anti-apoptosis pathway, such as loss of genomic, microtubule stability and cell cycle regulation [14]. Furthermore, the prevalence of DAPK promoter methylation did not correlate with that of K-ras mutations (p = 0.735), consistent with previous data [11,21], suggesting that DAPK promoter methylation and K-ras mutations are independent events in non-small cell lung tumorigenesis.
###end p 37
###begin p 38
###xml 18 26 18 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A </italic>
###xml 99 103 99 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 226 230 226 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 247 250 247 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53</italic>
###xml 265 267 265 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 340 348 340 348 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A </italic>
###xml 373 377 373 377 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 404 408 404 408 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 425 428 425 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53</italic>
###xml 443 445 443 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 200 208 <span type="species:ncbi:9606">patients</span>
###xml 552 560 <span type="species:ncbi:9606">patients</span>
The prevalence of RASSF1A promoter methylation in the present study did not correlate with that of p53 mutations (p = 0.212). Previously, Endoh et al found a similar trend in their study of 100 NSCLC patients (21/56 wild-type p53 vs. 21/44 mutant p53, p = 0.3165) [41]. On the other hand, Tomizawa et al observed a weak association between RASSF1A promoter methylation and p53 mutations (19/73 wild-type p53 vs. 16/37 mutant p53, p = 0.0842) [46]. The discrepancy may be in part due to the difference in tumor stages in the different studies, with all patients in stage I lung adenocarcinoma tumors in Tomizawa's study and a mixed of tumors of different types [adenocarcinoma: 67% (67/100) and 59% (72/122)] and stages [stage I: 57% (57/100) and 44% (54/122)] in Endoh's and our studies.
###end p 38
###begin p 39
###xml 53 58 53 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAPK </italic>
###xml 82 86 82 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 120 125 120 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAPK </italic>
###xml 150 154 150 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 200 204 200 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAPK</italic>
###xml 271 275 271 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 424 428 424 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 459 461 459 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 485 490 485 490 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAPK </italic>
###xml 515 519 515 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 595 597 595 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 662 664 662 664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 665 667 665 667 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 686 691 686 691 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAPK </italic>
###xml 761 764 761 764 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53</italic>
###xml 807 811 807 811 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 574 582 <span type="species:ncbi:9606">patients</span>
We observed no correlation between the prevalence of DAPK methylation and that of p53 mutations (p = 0.331), indicating DAPK promoter methylation and p53 mutations may be independent events in NSCLC. DAPK, and a few other genes, have been reported to operate upstream to p53 to induce apoptosis. For instance, Raveh et al found that the inactivation or loss of DAPK alone significantly reduces but not completely eliminates p53 in response to c-Myc or E2F-1 [29]. Kim et al found that DAPK promoter methylation and p53 mutations were not related in their study of 185 NSCLC patients (p = 0.85) [21]. Thus, our results are consistent with those of these studies [21,29], suggesting that DAPK may be wired simultaneously to a few independent upstream branches of p53, and may be involved in apoptosis without p53 participation.
###end p 39
###begin p 40
###xml 54 59 54 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 96 104 96 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A </italic>
###xml 107 112 107 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAPK </italic>
###xml 212 220 212 220 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A </italic>
###xml 245 250 245 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 278 280 278 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 297 299 297 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 384 389 384 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAPK </italic>
###xml 654 656 654 656 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 676 681 676 681 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 686 691 686 691 <italic xmlns:xlink="http://www.w3.org/1999/xlink">-ras </italic>
###xml 839 847 839 847 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A </italic>
###xml 887 892 887 892 <italic xmlns:xlink="http://www.w3.org/1999/xlink">-ras </italic>
###xml 895 900 895 900 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 995 997 995 997 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 1000 1004 1000 1004 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR</italic>
###xml 1006 1011 1006 1011 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER-2</italic>
###xml 1018 1023 1018 1023 <italic xmlns:xlink="http://www.w3.org/1999/xlink">-ras </italic>
###xml 1136 1141 1136 1141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 1259 1263 1259 1263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16 </italic>
###xml 1280 1285 1280 1285 <italic xmlns:xlink="http://www.w3.org/1999/xlink">-ras </italic>
###xml 1443 1451 1443 1451 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A </italic>
###xml 33 41 <span type="species:ncbi:9606">patients</span>
###xml 602 610 <span type="species:ncbi:9606">patients</span>
###xml 784 792 <span type="species:ncbi:9606">patients</span>
###xml 981 987 <span type="species:ncbi:8164">Suzuki</span>
###xml 1100 1108 <span type="species:ncbi:9606">patients</span>
Results of our study based on 70 patients showed that EGFR mutations did not correlate with the RASSF1A or DAPK gene promoter methylation. Previously, there are only two studies investigating the relationship of RASSF1A promoter methylation and EGFR mutation, reporting absent [13] or borderline [47] correlation between these two events. The relationship between these mutations and DAPK promoter methylation has not been previously investigated. Furthermore, there have been only two previous studies of epigenetic and genetic alterations in multiple genes in lung tumors, both involving lung cancer patients from Japan. In the study by Toyooka et al [13], mutations in the EGFR and K-ras genes were compared with promoter methylation of five genes in lung adenocarcinomas from 164 patients. There was no significant association between RASSF1A promoter methylation frequency and the K-ras or EGFR mutation frequency. Our data are in agreement with this finding. In the study by Suzuki et al [40], EGFR, HER-2, and K-ras mutations were compared with promoter methylation of nine genes in 150 NSCLC patients. The authors observed that EGFR mutation had an inverse correlation with promoter methylation of the secreted protein acidic and rich in cysteine and p16 genes. However, K-ras mutations were detected at a lower fraction of the tumor, compared with our study (6 out of 150 versus 36 out of 122) and was not investigated in relation to RASSF1A methylation.
###end p 40
###begin p 41
###xml 176 184 176 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASFF1A </italic>
###xml 245 250 245 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">-ras </italic>
###xml 261 263 261 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 264 266 264 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 381 389 381 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A </italic>
###xml 437 442 437 442 <italic xmlns:xlink="http://www.w3.org/1999/xlink">-ras </italic>
###xml 462 464 462 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
The relationship between epigenetic and genetic alterations has also been investigated in other tumor types. For instance, in sporadic colorectal cancer and pancreatic cancer, RASFF1A promoter methylation was found predominantly in tumors with K-ras wild type [48,49]. Another study showed that sporadic colorectal cancer exhibiting microsatellite instability harbored concomitant RASSF1A gene promoter methylation and mutations in the K-ras and/or B-raf genes [50].
###end p 41
###begin p 42
###xml 212 219 <span type="species:ncbi:9606">patient</span>
Taken together, results from these studies and our present study indicated the need for further investigation of the interaction between genetic and epigenetic alterations in lung tumors in an ethnically diverse patient population in order to further understand the development of lung cancer.
###end p 42
###begin title 43
Conclusion
###end title 43
###begin p 44
###xml 28 36 28 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A </italic>
###xml 40 45 40 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAPK </italic>
###xml 269 277 269 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A </italic>
###xml 516 519 516 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras</italic>
###xml 521 524 521 524 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53</italic>
###xml 529 534 529 534 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 84 92 <span type="species:ncbi:9606">patients</span>
###xml 466 474 <span type="species:ncbi:9606">patients</span>
Promoter methylation of the RASSF1A and DAPK genes was frequent in lung tumors from patients with primarily NSCLC, all of whom were Caucasian and from the Western Pennsylvania region. Furthermore, there was a significant association between promoter methylation of the RASSF1A gene and tumor histology, specifically adenocarcinoma. However, there was no significant association of the prevalence of promoter methylation of either gene with the smoking status of the patients or with the status of mutations in the K-ras, p53, or EGFR gene, suggesting each of these events may occur independently in lung tumorigenesis.
###end p 44
###begin title 45
Competing interests
###end title 45
###begin p 46
The author(s) declare that they have no competing interests.
###end p 46
###begin title 47
Authors' contributions
###end title 47
###begin p 48
###xml 84 88 84 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras </italic>
###xml 92 96 92 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 244 252 <span type="species:ncbi:9606">patients</span>
YL carried out the methylation analysis, and drafted the manuscript; WG performed K-ras and p53 mutations and participated in the analysis and interpretation of data; JMS and JDL provided lung tumor samples, demographic/clinical information of patients and data interpretation; JLW performed statistical analysis and interpretation of data; PK designed and supervised the study, analyzed and interpreted data.
###end p 48
###begin title 49
Pre-publication history
###end title 49
###begin p 50
The pre-publication history for this paper can be accessed here:
###end p 50
###begin p 51

###end p 51
###begin title 52
Acknowledgements
###end title 52
###begin p 53
We thank Dr. Dianxu Ren, Center for Research & Evaluation, School of Nursing & Department of Biostatistics, University of Pittsburgh, for helping in the statistical analysis of data. This work was supported by grants from the American Cancer Society (grant #RPG-99-161-01-CNE and grant #RSG-99-161-04-CNE).
###end p 53
###begin article-title 54
###xml 0 7 <span type="species:ncbi:4097">Tobacco</span>
Tobacco smoke carcinogens and lung cancer
###end article-title 54
###begin article-title 55
Detection of K-ras mutations in lung carcinomas: relationship to prognosis
###end article-title 55
###begin article-title 56
###xml 98 103 <span type="species:ncbi:9606">women</span>
Comparison of mutations in the p53 and K-ras genes in lung carcinomas from smoking and nonsmoking women
###end article-title 56
###begin article-title 57
Cigarette smoking is strongly associated with mutation of the K-ras gene inpatients with primary adenocarcinoma of the lung
###end article-title 57
###begin article-title 58
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib
###end article-title 58
###begin article-title 59
Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications
###end article-title 59
###begin article-title 60
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
###end article-title 60
###begin article-title 61
###xml 44 51 <span type="species:ncbi:4097">tobacco</span>
p53 mutations and exposure to environmental tobacco smoke in a multicenter study on lung cancer
###end article-title 61
###begin article-title 62
###xml 73 80 <span type="species:ncbi:4097">tobacco</span>
p16(INK4a) and histology-specific methylation of CpG islands exposure to tobacco smoke in non-small cell lung cancer
###end article-title 62
###begin article-title 63
Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer
###end article-title 63
###begin article-title 64
Multiplicity of abnormal promoter methylation in lung adenocarcinomas from smokers and never smokers
###end article-title 64
###begin article-title 65
###xml 110 118 <span type="species:ncbi:9606">patients</span>
Aberrant promoter methylation of p16 and MGMT genes in lung tumors from smoking and never-smoking lung cancer patients
###end article-title 65
###begin article-title 66
Mutational and epigenetic evidence for independent pathways for lung adenocarcinomas arising in smokers and never smokers
###end article-title 66
###begin article-title 67
###xml 67 72 <span type="species:ncbi:9606">human</span>
Role of the Ras-association domain family tumor suppressor gene in human cancers
###end article-title 67
###begin article-title 68
Epigenetic inactivation of a RAS association domain familyprotein from the lung tumour suppressor locus 3p21.3
###end article-title 68
###begin article-title 69
Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression
###end article-title 69
###begin article-title 70
###xml 107 114 <span type="species:ncbi:4097">tobacco</span>
Hypermethylation of RASSF1A and BLU tumor suppressor genes in non-small cell lung cancer: implications for tobacco smoking during adolescence
###end article-title 70
###begin article-title 71
The DAP-kinase family of proteins: study of a novel group of calcium-regulated death-promoting kinases
###end article-title 71
###begin article-title 72
DAP kinase links the control of apoptosis to metastasis
###end article-title 72
###begin article-title 73
Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer
###end article-title 73
###begin article-title 74
Promoter methylation of DAP-kinase: association with advanced stage in non-small cell lung cancer
###end article-title 74
###begin article-title 75
Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction?
###end article-title 75
###begin article-title 76
Regulation of the DNA methyltransferase by the Ras-AP-1 signaling pathway
###end article-title 76
###begin article-title 77
Regulation of DNA methylation by the Ras signaling pathway
###end article-title 77
###begin article-title 78
Ras uses the novel tumor suppressor RASSF1 as an effector to mediate apoptosis
###end article-title 78
###begin article-title 79
Identification of a novel Ras-regulated proapoptotic pathway
###end article-title 79
###begin article-title 80
Cell signaling: life or death decisions of ras proteins
###end article-title 80
###begin article-title 81
The putative tumor suppressor RASSF1A homodimerizes and heterodimerizes with the Ras-GTP binding protein Nore1
###end article-title 81
###begin article-title 82
DAP kinase activates a p19ARF/p53-mediated apoptotic checkpoint to suppress oncogenic transformation
###end article-title 82
###begin article-title 83
p53 in growth control and neoplasia
###end article-title 83
###begin article-title 84
p53: puzzle and paradigm
###end article-title 84
###begin article-title 85
###xml 93 98 <span type="species:ncbi:9606">human</span>
Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia
###end article-title 85
###begin article-title 86
EGFR mutations in lung cancer: correlation with linical response to gefitinib therapy
###end article-title 86
###begin article-title 87
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
###end article-title 87
###begin article-title 88
Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands
###end article-title 88
###begin article-title 89
Predicting lung cancer by detecting aberrantpromoter methylation in sputum
###end article-title 89
###begin article-title 90
Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers
###end article-title 90
###begin article-title 91
Comparison of p53 mutations between adenocarcinoma and squamous cell carcinoma of the lung: unique spectra involving G to A transitions and G to T transversions in both histologic types
###end article-title 91
###begin article-title 92
Mutation and polymorphism in the EGFR-TK domain associated with lung cancer
###end article-title 92
###begin article-title 93
Exclusive mutation in epidermal growth factorreceptor gene, HER-2, and KRAS, and synchronous methylation of nonsmall cell lung cancer
###end article-title 93
###begin article-title 94
RASSF1A gene inactivation in non-small cell lung cancer and its clinical implication
###end article-title 94
###begin article-title 95
Hypermethylation of RASSF1A promoter is associated with theage at starting smoking and a poor prognosis in primary non-smallcell lung cancer
###end article-title 95
###begin article-title 96
Relationship of Ras association domain family 1 methylation and K-ras mutation in primary non-small cell lung cancer
###end article-title 96
###begin article-title 97
Epigenetic down-regulation of death-associated protein kinase in lung cancers
###end article-title 97
###begin article-title 98
###xml 80 87 <span type="species:ncbi:4097">tobacco</span>
Differential DNA hypermethylation of critical genes mediates the stage-specific tobacco smoke-induced neoplastic progression of lung cancer
###end article-title 98
###begin article-title 99
Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma
###end article-title 99
###begin article-title 100
###xml 96 104 <span type="species:ncbi:9606">patients</span>
Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer
###end article-title 100
###begin article-title 101
K-ras mutations and RASSF1A promoter methylation in colorectal cancer
###end article-title 101
###begin article-title 102
###xml 98 103 <span type="species:ncbi:9606">human</span>
Epigenetic inactivation of the Ras-association domain family 1 (RASSF1A) gene and its function in human carcinogenesis
###end article-title 102
###begin article-title 103
Concomitant RASSF1A hypermethylation and KRAS/BRAF mutations occur preferentially in MSI sporadic colorectal cancer
###end article-title 103
###begin title 104
Figures and Tables
###end title 104
###begin p 105
###xml 13 21 13 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A </italic>
###xml 25 30 25 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAPK </italic>
###xml 0 57 0 57 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Detection of <italic>RASSF1A </italic>and <italic>DAPK </italic>promoter methylation by MSP</bold>
###xml 98 106 98 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A </italic>
###xml 109 113 109 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAPK</italic>
###xml 156 164 156 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A </italic>
###xml 167 171 167 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAPK</italic>
Detection of RASSF1A and DAPK promoter methylation by MSP. M indicates the presence of methylated RASSF1A or DAPK. U indicates the presence of unmethylated RASSF1A or DAPK. All samples were performed twice and representative data are shown.
###end p 105
###begin p 106
###xml 46 54 <span type="species:ncbi:9606">patients</span>
Demographic and clinical profile of 122 NSCLC patients
###end p 106
###begin p 107
*: standard deviation
###end p 107
###begin p 108
###xml 30 35 30 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAPK </italic>
###xml 39 47 39 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A </italic>
Logistic regression models of DAPK and RASSF1A promoter methylation (n = 122)
###end p 108
###begin p 109
OR: odds ratio; CI: confidence interval.
###end p 109
###begin p 110
dagger: the group of other tumor types vs. adenocarcinoma.
###end p 110
###begin p 111
double dagger: the group of other stages vs. stage I.
###end p 111

